Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EC education

This article was originally published in The Tan Sheet

Executive Summary

Identical bills to establish public education awareness programs on emergency contraception introduced in Senate, House March 6. "Emergency Contraception Education Act" (S 1990) would provide $10 mil. per year for five years for the CDC and Health Resources & Services Administration to develop and disseminate consumer, healthcare professional information describing "use, safety, efficacy and availability" of ECs. Introduced by Sen. Patty Murray (D-Wash.), the bill was referred to the Health & Education Committee. Its twin in the House was introduced by Rep. Louise Slaughter (D-N.Y.); HR 3887 was referred to the Commerce Committee. Bills come one week after Rep. Melissa Hart (R-Penn.) introduced a measure that would bar federal education funding for schools that provide access to ECs; HR 3805 was referred to the Education Committee...

You may also be interested in...



Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Teva’s Austedo Fails In Tourette’s Syndrome

Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.

Topics

UsernamePublicRestriction

Register

PS093722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel